Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice
Identifieur interne : 001537 ( Pmc/Curation ); précédent : 001536; suivant : 001538Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice
Auteurs : Christopher M. Coleman [États-Unis] ; Ye V. Liu [États-Unis] ; Haiyan Mu [États-Unis] ; Justin K. Taylor [États-Unis] ; Michael Massare [États-Unis] ; David C. Flyer [États-Unis] ; Gregory M. Glenn [États-Unis] ; Gale E. Smith [États-Unis] ; Matthew B. Frieman [États-Unis]Source :
- Vaccine [ 0264-410X ] ; 2014.
Abstract
Emergence of MERS-CoV demonstrates the need for novel vaccine strategies against coronaviruses. Production of novel nanoparticle vaccine containing full spike protein of MERS-CoV and SARS-CoV. Higher titer neutralizing antibody produced in vaccinated mice. Vaccination in combination with a new adjuvant, Matrix M1, boosts neutralizing antibody titer.
Url:
DOI: 10.1016/j.vaccine.2014.04.016
PubMed: 24736006
PubMed Central: 4058772
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001537
Links to Exploration step
PMC:4058772Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice</title><author><name sortKey="Coleman, Christopher M" sort="Coleman, Christopher M" uniqKey="Coleman C" first="Christopher M." last="Coleman">Christopher M. Coleman</name><affiliation wicri:level="1"><nlm:aff id="aff0005">University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201</wicri:regionArea></affiliation></author><author><name sortKey="Liu, Ye V" sort="Liu, Ye V" uniqKey="Liu Y" first="Ye V." last="Liu">Ye V. Liu</name><affiliation wicri:level="1"><nlm:aff id="aff0010">Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852</wicri:regionArea></affiliation></author><author><name sortKey="Mu, Haiyan" sort="Mu, Haiyan" uniqKey="Mu H" first="Haiyan" last="Mu">Haiyan Mu</name><affiliation wicri:level="1"><nlm:aff id="aff0010">Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852</wicri:regionArea></affiliation></author><author><name sortKey="Taylor, Justin K" sort="Taylor, Justin K" uniqKey="Taylor J" first="Justin K." last="Taylor">Justin K. Taylor</name><affiliation wicri:level="1"><nlm:aff id="aff0005">University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201</wicri:regionArea></affiliation></author><author><name sortKey="Massare, Michael" sort="Massare, Michael" uniqKey="Massare M" first="Michael" last="Massare">Michael Massare</name><affiliation wicri:level="1"><nlm:aff id="aff0010">Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852</wicri:regionArea></affiliation></author><author><name sortKey="Flyer, David C" sort="Flyer, David C" uniqKey="Flyer D" first="David C." last="Flyer">David C. Flyer</name><affiliation wicri:level="1"><nlm:aff id="aff0010">Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852</wicri:regionArea></affiliation></author><author><name sortKey="Glenn, Gregory M" sort="Glenn, Gregory M" uniqKey="Glenn G" first="Gregory M." last="Glenn">Gregory M. Glenn</name><affiliation wicri:level="1"><nlm:aff id="aff0010">Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852</wicri:regionArea></affiliation></author><author><name sortKey="Smith, Gale E" sort="Smith, Gale E" uniqKey="Smith G" first="Gale E." last="Smith">Gale E. Smith</name><affiliation wicri:level="1"><nlm:aff id="aff0010">Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852</wicri:regionArea></affiliation></author><author><name sortKey="Frieman, Matthew B" sort="Frieman, Matthew B" uniqKey="Frieman M" first="Matthew B." last="Frieman">Matthew B. Frieman</name><affiliation wicri:level="1"><nlm:aff id="aff0005">University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">24736006</idno><idno type="pmc">4058772</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058772</idno><idno type="RBID">PMC:4058772</idno><idno type="doi">10.1016/j.vaccine.2014.04.016</idno><date when="2014">2014</date><idno type="wicri:Area/Pmc/Corpus">001537</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001537</idno><idno type="wicri:Area/Pmc/Curation">001537</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001537</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice</title><author><name sortKey="Coleman, Christopher M" sort="Coleman, Christopher M" uniqKey="Coleman C" first="Christopher M." last="Coleman">Christopher M. Coleman</name><affiliation wicri:level="1"><nlm:aff id="aff0005">University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201</wicri:regionArea></affiliation></author><author><name sortKey="Liu, Ye V" sort="Liu, Ye V" uniqKey="Liu Y" first="Ye V." last="Liu">Ye V. Liu</name><affiliation wicri:level="1"><nlm:aff id="aff0010">Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852</wicri:regionArea></affiliation></author><author><name sortKey="Mu, Haiyan" sort="Mu, Haiyan" uniqKey="Mu H" first="Haiyan" last="Mu">Haiyan Mu</name><affiliation wicri:level="1"><nlm:aff id="aff0010">Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852</wicri:regionArea></affiliation></author><author><name sortKey="Taylor, Justin K" sort="Taylor, Justin K" uniqKey="Taylor J" first="Justin K." last="Taylor">Justin K. Taylor</name><affiliation wicri:level="1"><nlm:aff id="aff0005">University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201</wicri:regionArea></affiliation></author><author><name sortKey="Massare, Michael" sort="Massare, Michael" uniqKey="Massare M" first="Michael" last="Massare">Michael Massare</name><affiliation wicri:level="1"><nlm:aff id="aff0010">Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852</wicri:regionArea></affiliation></author><author><name sortKey="Flyer, David C" sort="Flyer, David C" uniqKey="Flyer D" first="David C." last="Flyer">David C. Flyer</name><affiliation wicri:level="1"><nlm:aff id="aff0010">Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852</wicri:regionArea></affiliation></author><author><name sortKey="Glenn, Gregory M" sort="Glenn, Gregory M" uniqKey="Glenn G" first="Gregory M." last="Glenn">Gregory M. Glenn</name><affiliation wicri:level="1"><nlm:aff id="aff0010">Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852</wicri:regionArea></affiliation></author><author><name sortKey="Smith, Gale E" sort="Smith, Gale E" uniqKey="Smith G" first="Gale E." last="Smith">Gale E. Smith</name><affiliation wicri:level="1"><nlm:aff id="aff0010">Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852</wicri:regionArea></affiliation></author><author><name sortKey="Frieman, Matthew B" sort="Frieman, Matthew B" uniqKey="Frieman M" first="Matthew B." last="Frieman">Matthew B. Frieman</name><affiliation wicri:level="1"><nlm:aff id="aff0005">University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201</wicri:regionArea></affiliation></author></analytic><series><title level="j">Vaccine</title><idno type="ISSN">0264-410X</idno><idno type="eISSN">1873-2518</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><title>Highlights</title><p><list list-type="simple" id="lis0005"><list-item id="lsti0005"><label>•</label><p id="par0005">Emergence of MERS-CoV demonstrates the need for novel vaccine strategies against coronaviruses.</p></list-item><list-item id="lsti0010"><label>•</label><p id="par0010">Production of novel nanoparticle vaccine containing full spike protein of MERS-CoV and SARS-CoV.</p></list-item><list-item id="lsti0015"><label>•</label><p id="par0015">Higher titer neutralizing antibody produced in vaccinated mice.</p></list-item><list-item id="lsti0020"><label>•</label><p id="par0020">Vaccination in combination with a new adjuvant, Matrix M1, boosts neutralizing antibody titer.</p></list-item></list></p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Jackwood, M W" uniqKey="Jackwood M">M.W. Jackwood</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Song, D" uniqKey="Song D">D. Song</name></author><author><name sortKey="Park, B" uniqKey="Park B">B. Park</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ding, Y" uniqKey="Ding Y">Y. Ding</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Drosten, C" uniqKey="Drosten C">C. Drosten</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kuiken, T" uniqKey="Kuiken T">T. Kuiken</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lau, S K" uniqKey="Lau S">S.K. Lau</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Poon, L L" uniqKey="Poon L">L.L. Poon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ge, X Y" uniqKey="Ge X">X.Y. Ge</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van Boheemen, S" uniqKey="Van Boheemen S">S. van Boheemen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zaki, A M" uniqKey="Zaki A">A.M. Zaki</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mailles, A" uniqKey="Mailles A">A. Mailles</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Masters, P S" uniqKey="Masters P">P.S. Masters</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Belouzard, S" uniqKey="Belouzard S">S. Belouzard</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Qiu, M" uniqKey="Qiu M">M. Qiu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Du, L" uniqKey="Du L">L. Du</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhu, X" uniqKey="Zhu X">X. Zhu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tseng, C T Et Al" uniqKey="Tseng C">C.T.et al. Tseng</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Spruth, M" uniqKey="Spruth M">M. Spruth</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Qin, E" uniqKey="Qin E">E. Qin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lin, J T" uniqKey="Lin J">J.T. Lin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bolles, M" uniqKey="Bolles M">M. Bolles</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li, J" uniqKey="Li J">J. Li</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="He, Y" uniqKey="He Y">Y. He</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shim, B S" uniqKey="Shim B">B.S. Shim</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bisht, H" uniqKey="Bisht H">H. Bisht</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Feng, Q" uniqKey="Feng Q">Q. Feng</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yang, Z Y" uniqKey="Yang Z">Z.Y. Yang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Martin, J E" uniqKey="Martin J">J.E. Martin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lu, B" uniqKey="Lu B">B. Lu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liu, Y V" uniqKey="Liu Y">Y.V. Liu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lu, X" uniqKey="Lu X">X. Lu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bai, B Et Al" uniqKey="Bai B">B.et al. Bai</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lokugamage, K G" uniqKey="Lokugamage K">K.G. Lokugamage</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lu, B" uniqKey="Lu B">B. Lu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Almazan, F" uniqKey="Almazan F">F. Almazan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Song, F" uniqKey="Song F">F. Song</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="De Groot, A S" uniqKey="De Groot A">A.S. De Groot</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Roberts, A" uniqKey="Roberts A">A. Roberts</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Reed, L J" uniqKey="Reed L">L.J. Reed</name></author><author><name sortKey="Muench, H" uniqKey="Muench H">H. Muench</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Simons, K" uniqKey="Simons K">K. Simons</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Smith, G" uniqKey="Smith G">G. Smith</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Glenn, G M" uniqKey="Glenn G">G.M. Glenn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lovgren Bengtsson, K" uniqKey="Lovgren Bengtsson K">K. Lovgren Bengtsson</name></author><author><name sortKey="Morein, B" uniqKey="Morein B">B. Morein</name></author><author><name sortKey="Osterhaus, A D" uniqKey="Osterhaus A">A.D. Osterhaus</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cox, R J" uniqKey="Cox R">R.J. Cox</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Devitt, E" uniqKey="Devitt E">E. Devitt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Coleman, C M" uniqKey="Coleman C">C.M. Coleman</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccine</journal-id><journal-id journal-id-type="iso-abbrev">Vaccine</journal-id><journal-title-group><journal-title>Vaccine</journal-title></journal-title-group><issn pub-type="ppub">0264-410X</issn><issn pub-type="epub">1873-2518</issn><publisher><publisher-name>Elsevier Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24736006</article-id><article-id pub-id-type="pmc">4058772</article-id><article-id pub-id-type="publisher-id">S0264-410X(14)00518-0</article-id><article-id pub-id-type="doi">10.1016/j.vaccine.2014.04.016</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice</article-title></title-group><contrib-group><contrib contrib-type="author" id="aut0005"><name><surname>Coleman</surname><given-names>Christopher M.</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="aut0010"><name><surname>Liu</surname><given-names>Ye V.</given-names></name><xref rid="aff0010" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="aut0015"><name><surname>Mu</surname><given-names>Haiyan</given-names></name><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="aut0020"><name><surname>Taylor</surname><given-names>Justin K.</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="aut0025"><name><surname>Massare</surname><given-names>Michael</given-names></name><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="aut0030"><name><surname>Flyer</surname><given-names>David C.</given-names></name><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="aut0032"><name><surname>Glenn</surname><given-names>Gregory M.</given-names></name><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="aut0035"><name><surname>Smith</surname><given-names>Gale E.</given-names></name><xref rid="aff0010" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="aut0040"><name><surname>Frieman</surname><given-names>Matthew B.</given-names></name><email>mfrieman@som.umaryland.edu</email><email>matt.frieman@gmail.com</email><xref rid="aff0005" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">1</xref><xref rid="cor0005" ref-type="corresp">⁎</xref></contrib></contrib-group><aff id="aff0005"><label>a</label>University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201, USA</aff><aff id="aff0010"><label>b</label>Novavax, Inc. 22 Firstfield Rd, Gaithersburg, MD 20852, USA</aff><author-notes><corresp id="cor0005"><label>⁎</label>Corresponding author. Tel.: +1 417062539; fax: +1 4107066970. <email>mfrieman@som.umaryland.edu</email><email>matt.frieman@gmail.com</email></corresp><fn id="fn1"><label>1</label><p id="npar0005">These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="pmc-release"><day>13</day><month>4</month><year>2014</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on .</pmc-comment>
<pub-date pub-type="ppub"><day>30</day><month>5</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>13</day><month>4</month><year>2014</year></pub-date><volume>32</volume><issue>26</issue><fpage>3169</fpage><lpage>3174</lpage><history><date date-type="received"><day>15</day><month>1</month><year>2014</year></date><date date-type="rev-recd"><day>18</day><month>3</month><year>2014</year></date><date date-type="accepted"><day>2</day><month>4</month><year>2014</year></date></history><permissions><copyright-statement>Copyright © 2014 Elsevier Ltd. All rights reserved.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Elsevier Ltd</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract abstract-type="author-highlights" id="abs0005"><title>Highlights</title><p><list list-type="simple" id="lis0005"><list-item id="lsti0005"><label>•</label><p id="par0005">Emergence of MERS-CoV demonstrates the need for novel vaccine strategies against coronaviruses.</p></list-item><list-item id="lsti0010"><label>•</label><p id="par0010">Production of novel nanoparticle vaccine containing full spike protein of MERS-CoV and SARS-CoV.</p></list-item><list-item id="lsti0015"><label>•</label><p id="par0015">Higher titer neutralizing antibody produced in vaccinated mice.</p></list-item><list-item id="lsti0020"><label>•</label><p id="par0020">Vaccination in combination with a new adjuvant, Matrix M1, boosts neutralizing antibody titer.</p></list-item></list></p></abstract><abstract id="abs0010"><p>Development of vaccination strategies for emerging pathogens are particularly challenging because of the sudden nature of their emergence and the long process needed for traditional vaccine development. Therefore, there is a need for development of a rapid method of vaccine development that can respond to emerging pathogens in a short time frame.</p><p>The emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003 and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in late 2012 demonstrate the importance of coronaviruses as emerging pathogens. The spike glycoproteins of coronaviruses reside on the surface of the virion and are responsible for virus entry. The spike glycoprotein is the major immunodominant antigen of coronaviruses and has proven to be an excellent target for vaccine designs that seek to block coronavirus entry and promote antibody targeting of infected cells.</p><p>Vaccination strategies for coronaviruses have involved live attenuated virus, recombinant viruses, non-replicative virus-like particles expressing coronavirus proteins or DNA plasmids expressing coronavirus genes. None of these strategies has progressed to an approved human coronavirus vaccine in the ten years since SARS-CoV emerged. Here we describe a novel method for generating MERS-CoV and SARS-CoV full-length spike nanoparticles, which in combination with adjuvants are able to produce high titer antibodies in mice.</p></abstract><kwd-group id="kwd0005"><title>Keywords</title><kwd>Middle East Respiratory Syndrome Coronavirus</kwd><kwd>Severe Acute Respiratory Syndrome Coronavirus</kwd><kwd>Neutralizing antibody</kwd><kwd>Vaccine</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001537 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 001537 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Pmc
|étape= Curation
|type= RBID
|clé= PMC:4058772
|texte= Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:24736006" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |